Published on
Dec 9, 2025
Mirum to buy Bluejay for up to $820m in rare liver disease push
Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics in a deal worth up to $820m, adding a Phase III liver disease candidate to its portfolio. According to the agreement, US-based Mirum will pay $250m in cash and $370m in its own stock upfront …
Source:
Pharmaceutical Technology
-
Neutral
